Vir Biotechnology reports ~$781 million year-end cash, runway into Q4 2027
Vir Biotechnology said it had approximately $781 million in cash, cash equivalents and investments as of December 31, 2025, an unaudited figure, and that this balance is expected to fund operations into the fourth quarter of 2027, which it links to the Norgine licensing agreement and continued financial discipline. It also released updated Phase 2 SOLSTICE data for its chronic hepatitis delta combination therapy, with 88% of participants evaluated through Week 96 reaching undetectable hepatitis delta virus RNA versus 46% on the antibody alone. The filing contains no full-year revenue or profit figures, which the company expects to report in late February 2026.
Key points
- Preliminary, unaudited cash, cash equivalents and investments of approximately $781 million as of December 31, 2025; full fourth-quarter and 2025 results expected in late February 2026.
- Cash runway extended into the fourth quarter of 2027, tied by the company to the Norgine license for chronic hepatitis delta in Europe, Australia and New Zealand.
- SOLSTICE Phase 2: undetectable HDV RNA at Week 96 in 88% (21/24) of combination participants versus 46% (11/24) on tobevibart alone.
- Company to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PT.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.